ID   44-3A6
AC   CVCL_ZW10
SY   MCA 44-3A6
DR   ATCC; HB-8986
DR   Wikidata; Q102113452
RX   Patent=US4816402;
RX   PubMed=2413999;
RX   PubMed=31807015;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8986.
CC   Monoclonal antibody isotype: IgG1.
CC   Monoclonal antibody target: Human labyrinthin.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
CA   Hybridoma
DT   Created: 29-10-20; Last updated: 21-03-23; Version: 4
//
RX   Patent=US4816402;
RA   Rosen S.T., Radosevich J.A., Ma Y.-X.;
RT   "Murine hybridoma and diagnostic antibody produced thereby.";
RL   Patent number US4816402, 28-Mar-1989.
//
RX   PubMed=2413999;
RA   Radosevich J.A., Ma Y.-X., Lee I., Salwen H.R., Gould V.E., Rosen S.T.;
RT   "Monoclonal antibody 44-3A6 as a probe for a novel antigen found on
RT   human lung carcinomas with glandular differentiation.";
RL   Cancer Res. 45:5808-5812(1985).
//
RX   PubMed=31807015; DOI=10.2147/OTT.S220445;
RA   Radosevich J.A., Babich M.;
RT   "Labyrinthin, the tumor marker recognized by MCA 44-3A6: a case for
RT   pan-tumor markers as targets to treat cancer.";
RL   Onco Targets Ther. 12:9351-9354(2019).
//